Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated”  Off-the-Shelf Natural Killer Cell Therapy

An Interview with: Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA CHICAGO – Several patients with acute myeloid leukemia, who were treated with SENTI-202, a first-in-class chimeric antigen receptor (CAR) natural killer (NK) cell therapy, experienced complete remission after not responding to (or having relapsed following) prior treatments, according to interim results from the phase one SENTI-202-101 clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research. During the conference Audio Journal of Oncology correspondent Peter Goodwin met up with the lead author of the study, Stephen Strickland, Jr. MD MSCI, Director of Leukemia Research and Executive Chair of the Leukemia Research Committee at the Sarah Cannon Research Institute in Nashville, TN.   AACR Abstract title: First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data

There are no comments yet.

Please log in to write the first comment.